# KEYNOTE-199 (NCT02787005)

> Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab; pembrolizumab plus enzalutamide
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02787005
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: Pembrolizumab
- Enrollment: 388
- Primary outcome: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohort 1, Cohort 2, Cohort 4 and Cohorts 1 and 2 Combined)

## Indexed commentary on KEYNOTE-199 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 2 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-199-nct02787005

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02787005", "email": "<work email>"}; the inbox owner confirms by the emailed link.